Condition
Immune Senescence
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 4 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07000734Phase 2Completed
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
NCT00860197Not ApplicableCompletedPrimary
Immune Benefits of Coffee
NCT00461695Phase 4CompletedPrimary
Influence of Persistent CMV-infection on Immune Senescence
NCT00926250Not ApplicableTerminatedPrimary
Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults
Showing all 4 trials